Literature DB >> 24649109

Expression levels of CD28, CTLA-4, PD-1 and Tim-3 as novel indicators of T-cell immune function in patients with chronic hepatitis B virus infection.

Lin Wang1, Chunnan Zhao1, Qunxin Peng1, Jinfang Shi1, Guohao Gu1.   

Abstract

Chronic hepatitis B (CHB) is one of the most common types of infectious diseases worldwide. The interaction between hepatitis B virus (HBV) and the host immune response is vital for the clinical outcome of HBV infection. Costimulatory signals are key factors for the host immune response and play a critical role in innate immunity, particularly antiviral immunity. The aim of the present study was to investigate the correlation between the expression levels of costimulatory molecules and the different states of CHB infection, including the expression levels prior to and following treatment with antiviral agents. The expression levels of CD28, CTLA-4, PD-1, Tim-3 and T-cell subsets were determined by flow cytometry. The load of HBV DNA in the serum was detected by quantitative polymerase chain reaction and the serology markers, including HBeAg and alanine aminotransferase (ALT), were measured by conventional methods. Compared to the healthy control group, the expression levels of CD28 and CTLA-4 on CD4 T cells prior to and following treatment with antiviral agents (the pre- and post-treatment groups, respectively) were significantly decreased, while the expression levels of Tim-3 on CD4 and CD8 T cells were significantly increased. In addition, the expression levels of PD-1 on CD4 and CD8 T cells in the pre-treatment group were significantly increased compared to those in the post-treatment and healthy control groups. Moreover, the multivariate analysis revealed that the levels of ALT and HBV-DNA in the serum were significantly positively correlated with PD-1 expression levels. In conclusion, the expression levels of these costimulatory molecules reflect the immune dysfunction of T cells in patients with CHB and, combined with T-cell subset analysis may be used as a novel evaluation system of immune function in patients with HBV infection.

Entities:  

Keywords:  T-cell immune function; chronic hepatitis B; flow cytometry

Year:  2014        PMID: 24649109      PMCID: PMC3917748          DOI: 10.3892/br.2014.217

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  27 in total

Review 1.  The HLA system. First of two parts.

Authors:  J Klein; A Sato
Journal:  N Engl J Med       Date:  2000-09-07       Impact factor: 91.245

2.  PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver.

Authors:  Holly Maier; Masanori Isogawa; Gordon J Freeman; Francis V Chisari
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

3.  Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease.

Authors:  W Ray Kim; Steven L Flamm; Adrian M Di Bisceglie; Henry C Bodenheimer
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

Review 4.  Managing HBV in patients with impaired immunity.

Authors:  Karsten Wursthorn; Heiner Wedemeyer; Michael P Manns
Journal:  Gut       Date:  2010-06-04       Impact factor: 23.059

5.  [A retrospective study of clinical and pathological spectrum in 91 patients with chronic severe hepatitis B].

Authors:  Xu-hua Liu; Su-jun Zheng; Ke-jia Zu; Yu Chen; Yi-sen Chen; Tai-ling Wang; Zhong-ping Duan
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2010-10

6.  Genetic variations of PD1 and TIM3 are differentially and interactively associated with the development of cirrhosis and HCC in patients with chronic HBV infection.

Authors:  Zhu Li; Na Li; Qianqian Zhu; Guoyu Zhang; Qunying Han; Pingping Zhang; Meng Xun; Yawen Wang; Xiaoyan Zeng; Cuiling Yang; Zhengwen Liu
Journal:  Infect Genet Evol       Date:  2013-01-02       Impact factor: 3.342

7.  Influence of T-helper cell subsets and crossregulation in hepatitis B virus infection.

Authors:  D R Milich
Journal:  J Viral Hepat       Date:  1997       Impact factor: 3.728

8.  Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.

Authors:  Paola Fisicaro; Caterina Valdatta; Marco Massari; Elisabetta Loggi; Elisabetta Biasini; Luca Sacchelli; Maria Cristina Cavallo; Enrico M Silini; Pietro Andreone; Gabriele Missale; Carlo Ferrari
Journal:  Gastroenterology       Date:  2009-09-30       Impact factor: 22.682

9.  PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients.

Authors:  Guoping Peng; Shuping Li; Wei Wu; Xufei Tan; Yiqiong Chen; Zhi Chen
Journal:  Mol Immunol       Date:  2007-09-14       Impact factor: 4.407

10.  Tim-3 expression on peripheral T cell subsets correlates with disease progression in hepatitis B infection.

Authors:  Wei Wu; Yu Shi; Jie Li; Feng Chen; Zhi Chen; Min Zheng
Journal:  Virol J       Date:  2011-03-11       Impact factor: 4.099

View more
  16 in total

Review 1.  Host nucleotide polymorphism in hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Shilu Mathew; Hany Abdel-Hafiz; Abbas Raza; Kaneez Fatima; Ishtiaq Qadri
Journal:  World J Hepatol       Date:  2016-04-08

2.  The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy.

Authors:  Xiaolong Tang; Qingguo Li; Yongqiang Zhu; Donghui Zheng; Jingjing Dai; Wenxuan Ni; Jia Wei; Yubao Xue; Ke Chen; Wei Hou; Chao Zhang; Xiaojun Feng; Yong Liang
Journal:  Am J Transl Res       Date:  2015-03-15       Impact factor: 4.060

Review 3.  Restoring homeostasis of CD4⁺ T cells in hepatitis-B-virus-related liver fibrosis.

Authors:  Li-Sha Cheng; Yun Liu; Wei Jiang
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

4.  Regulation of HBV-specific CD8(+) T cell-mediated inflammation is diversified in different clinical presentations of HBV infection.

Authors:  Colin M Dinney; Lu-Dong Zhao; Charles D Conrad; Jay M Duker; Richard O Karas; Zhibin Hu; Michele A Hamilton; Thomas R Gillis; Thomas M Parker; Bing Fan; Andrew H Advani; Fred B Poordad; Paulette L Fauceglia; Kathrin M Kirsch; Peter T Munk; Marc P Ladanyi; Bernard A Bochner; Justin A Bekelman; Carla M Grandori; James C Olson; Ronald D Lechan; Ghassan M A Abou; Mark A Goodarzi
Journal:  J Microbiol       Date:  2015-10-02       Impact factor: 3.422

5.  Roles of PD-1, Tim-3 and CTLA-4 in immunoregulation in regulatory T cells among patients with sepsis.

Authors:  Dong-Na Gao; Zhi-Xiang Yang; Qing-Hui Qi
Journal:  Int J Clin Exp Med       Date:  2015-10-15

6.  Downregulated Tim-3 expression is responsible for the incidence and development of colorectal cancer.

Authors:  Ping Zhang; Yan Wang; Xue-Rong Liu; Shi-Ru Hong; Jian Yao
Journal:  Oncol Lett       Date:  2018-05-11       Impact factor: 2.967

7.  Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C.

Authors:  Solomon Owusu Sekyere; Pothakamuri Venkata Suneetha; Svenja Hardtke; Christine Susanne Falk; Julia Hengst; Michael Peter Manns; Markus Cornberg; Heiner Wedemeyer; Verena Schlaphoff
Journal:  Front Immunol       Date:  2015-06-10       Impact factor: 7.561

8.  Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4.

Authors:  Hanan H Rizk; Nadia M Hamdy; Nadia L Al-Ansari; Hala O El-Mesallamy
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

Review 9.  Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression.

Authors:  Arshi Khanam; Joel V Chua; Shyam Kottilil
Journal:  Int J Mol Sci       Date:  2021-05-23       Impact factor: 5.923

10.  Abnormal expression of Tim-3 antigen on peripheral blood T cells is associated with progressive disease in osteosarcoma patients.

Authors:  Hongliang Liu; Liqiang Zhi; Ning Duan; Pengxiao Su
Journal:  FEBS Open Bio       Date:  2016-07-09       Impact factor: 2.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.